awmsg logo



tenofovir disoproxil fumarate (Viread®)


Reference No. 1880

Publication date:
15/08/2013


Last review date:
30/08/2016

Appraisal information

tenofovir disoproxil fumarate (Viread®) 245 mg film-coated tablet
tenofovir disoproxil fumarate (Viread®) 33 mg/g granules


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 19/06/2013
AWMSG meeting date: 17/07/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2313
Ministerial ratification: 14/08/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis. Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age for whom a solid dosage form is not appropriate with: compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download